Introduction
Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase is driven by the BCR::ABL1 fusion protein. Scemblix offers a targeted treatment approach by binding to a specific pocket on the ABL portion of this protein and inhibiting its activity.
Scemblix is available as an oral tablet and can be used in several treatment settings for adults with Ph+ CML-CP. For eligible patients who face challenges accessing their medication, Prescription Hope may help navigate prescription assistance and treatment costs.
What Is the Scemblix Patient Assistance Program?
Pharmaceutical manufacturers have come to recognize the financial strain that name-brand medications place on their patients. Manufacturers alleviate that cost by enacted patient assistance programs, such as the Scemblix patient assistance program. Patient assistance programs allow qualified patients access to the name-brand medications they need without the name-brand medication cost.
However, patient assistance programs like Scemblix prescription assistance often require extensive research, documentation, and coordination with the pharmaceutical manufacturer and healthcare providers. This can lead to frustration, feeling overwhelmed, and confusion.
Prescription Hope is here to help.
How Expert Advocates Help Make Scemblix More Affordable
Personalized Medication Assistance
Prescription Hope’s Scemblix medication support provides qualified patients access to the name-brand medication they need at a lower cost than market rate.
Prescription Hope’s team of medication access advocates understands how difficult the process of applying for personalized prescription assistance can be, as well as maintaining long-term access. Our team helps with all the administrative needs of applying for personalized prescription assistance, including forms, documents and signatures, communication with healthcare providers, coordination with manufacturers, and more.
Ongoing Patient Support
Prescription Hope also offers long-term patient support services even after acceptance into a patient assistance program. Our long-term medication assistance includes refill scheduling, document updates, yearly renewals, program monitoring, and more.
Scemblix Price Comparison
vs
Estimated Retail Price*
30-Day Supply
Prescription Hope Price
Per Month, NO Matter The Retail Price
*Source: Drugs.com
Scemblix Patient Assistance Eligibility
Patients applying for Scemblix medication access need to understand the assistance requirements. Since patient assistance programs have strict requirements, patients should know whether they meet such criteria prior to applying. All patient assistance programs have qualifications set in the following areas:
Income: Each program sets its own patient income threshold requirements.
Insurance: Each program also sets its own requirements for a patient’s insurance coverage.
Prescription: All patients applying must have a valid prescription for their needed brand-name medication.
U.S. Residency: All patients must be legal US residents.
Simple Enrollment With Expert Support
Getting Started With Enrollment
Are you looking for Scemblix application support? Do you need help with your Scemblix patient assistance application? Prescription Hope’s application process can be accessed in 6 easy steps:
- Submit Information: Our online enrollment form takes just a few minutes to fill out.
- Advocate Contact: Once we receive your completed enrollment form, a patient advocate will reach out within 1-2 business days.
- Document Collection: After your prequalification goes through, our team will collect all necessary documents.
- Provider Coordination: Our team will also obtain any needed signatures from your healthcare providers.
- Program Submission: Once everything is in order, we submit your application to the patient assistance program and coordinate with the pharmaceutical manufacturer on your behalf.
- Medication Delivery: Patients typically receive their medication within 2 weeks of approval to the patient assistance program. All medications ship directly from the manufacturer to the patient’s door or doctor’s office.
Understanding Scemblix
How Scemblix Works
Scemblix is a first-in-class STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor. Asciminib binds to the ABL myristoyl pocket of the BCR::ABL1 fusion protein and inhibits its kinase activity.
Scemblix has activity against wild-type BCR::ABL1 and several mutant forms, including the T315I mutation.
What Conditions Does Scemblix Treat?
Scemblix is indicated for adults with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Its approved uses include newly diagnosed Ph+ CML-CP, previously treated Ph+ CML-CP, and Ph+ CML-CP with the T315I mutation.
The newly diagnosed indication was approved under accelerated approval based on major molecular response. Continued approval may depend upon verification of clinical benefit in confirmatory trials.
Benefits of Treatment
Scemblix targets the BCR::ABL1 protein that drives Philadelphia chromosome-positive CML. In the ASC4FIRST study of newly diagnosed Ph+ CML-CP, Scemblix produced a major molecular response in 68% of patients at 48 weeks and 74% at 96 weeks, compared with 49% and 52%, respectively, for investigator-selected TKIs. In previously treated patients and those with the T315I mutation, clinical studies also demonstrated major molecular responses.
Important Safety Information and Side Effects
Myelosuppression
Scemblix can cause severe thrombocytopenia and neutropenia. Anemia may also occur. Complete blood counts should be monitored regularly.
Pancreatic Toxicity
Pancreatitis and elevations in lipase and amylase can occur with this medication. Patients should be monitored for pancreatic toxicity, including monthly monitoring of pancreatic enzymes.
Hypertension
Scemblix can cause hypertension, including severe hypertension. Blood pressure should be monitored and managed as clinically indicated.
Hypersensitivity
Hypersensitivity reactions, including rash, edema, and bronchospasm, can occur with this medication.
Cardiovascular Toxicity
Cardiovascular events have occurred with this medication, including ischemic cardiac and central nervous system conditions, arterial thrombotic or embolic events, arrhythmias, and cardiac failure. Patients with cardiovascular risk factors require monitoring.
Embryo-Fetal Toxicity
This medication can cause embryo-fetal harm. Animal studies demonstrated embryo-fetal mortality, structural abnormalities, and other developmental effects. Pregnancy status should be verified before treatment. Females of reproductive potential should use effective contraception during treatment and for one week after the last dose.
Breastfeeding
There are no data on asciminib in human milk or its effects on a breastfed child. Women should not breastfeed during treatment and for one week after the last dose because of the potential for serious adverse reactions in a breastfed child.
Drug Interactions
Strong CYP3A4 inhibitors may increase asciminib exposure and the risk of adverse reactions, while strong CYP3A4 inducers may decrease exposure and potentially reduce effectiveness. Oral itraconazole solution containing hydroxypropyl-β-cyclodextrin should be avoided with Scemblix.
Scemblix can also affect certain CYP3A4, CYP2C9, P-gp, and BCRP substrates. Specific dose-dependent recommendations apply to some of these medications, and rosuvastatin should be avoided with this medication at all recommended doses.
Common Side Effects and Laboratory Abnormalities
Common adverse reactions occurring in at least 20% of patients include musculoskeletal pain, rash, fatigue, upper respiratory tract infection, headache, abdominal pain, joint pain, and diarrhea.
Common laboratory abnormalities include decreased lymphocytes, leukocytes, platelets, neutrophils, corrected calcium, and hemoglobin, as well as increased lipase, cholesterol, uric acid, liver enzymes, triglycerides, creatine kinase, and amylase.
Access to Multiple Medications
Some patients looking for specialty medication access are also looking for assistance with multiple prescriptions. Prescription Hope medication assistance is available for hundreds of name-brand medications.
However many medications are needed for your treatment, Prescription Hope medication access is available to you for the same great rate of $70.00 per month, per medication.
Why Choose Prescription Hope for Scemblix Assistance?
Patient-Focused Medication Support
For 20 years, Prescription Hope has offered personalized medication assistance services to everyday Americans from big cities to the country. Our team of patient advocates helps qualified patients access the name-brand medication they need at a lower cost than market value.
Simplified Access to Specialty Therapies
Prescription Hope charges a simple fee of $70.00 per month, per medication. That means no add-ons, hidden fees, surprise charges, or medication costs. If our team can’t help you save money, then you pay us nothing.
Ongoing Prescription Assistance
Prescription Hope helps qualified patients with more than just accessing name-brand medication at a low cost; we also help with long-term administrative tasks to help you keep your access to the medications you need at less cost than market rate. This includes refill scheduling, yearly renewals, document updates, program monitoring, and more.
Network Access
Our network spans America, and allows patients access to hundreds of name-brand medications and their associated patient assistance programs.
Prescription Hope’s Scemblix assistance can help you get the brand-name prescription support you need today!